| CURIS INC. NEW DL -,01 |
| USA |
| US2312694084 / A42DTL |
| CUS1 (Frankfurt) / CRIS (NASDAQ) |
| FRA:CUS1, ETR:CUS1, CUS1:GR, NASDAQ:CRIS |
| - |
| - |
|
Curis Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of human cancers. The company concentrates on first-in-class and differentiated drugs, primarily small-molecule inhibitors that targe..
>Volltext.. |
| 6.17 Mio. EUR |
| -5.64 Mio. EUR |
| 6.11 Mio. EUR |
| -29.55 Mio. EUR |
| -18.32 Mio. EUR |
| -20.67 EUR |
| 1.16 Mio. EUR |
| 12.98 Mio. EUR |
| -25.05 Mio. EUR |
| 1 |
| -40.96% |
| 52.96% |
| - |
| - |
| - |
| - |
| 13.08.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|